ArticleBMC endocrine disorders2025
Remodeling gut microbiota and enhancing SCFA production in mice: mechanisms of RS2 and arabinoxylan in ameliorating PCOS phenotypes.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Decoding the gut-adipose-ovary axis in polycystic ovary syndrome: from metabolic dysregulation to oncological risk modulation.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPolycystic ovary syndrome (PCOS) is linked to hyperandrogenism and gut microbiota dysbiosis. Dietary fibers (DFs), such as resistant starch type 2 (RS2) and arabinoxylan (AX), modulate the gut microbiota and produce short-chain fatty acid (SCFA), potentially ameliorating PCOS symptoms. This study investigated the therapeutic potential of RS2 and AX in a mouse model of letrozole-induced PCOS and explored the underlying mechanisms involving the gut microbiota-SCFA-liver signaling pathways.
methodsLetrozole-induced PCOS mice were divided into six groups: control (C), RS2 (R), AX (A), PCOS model (M), RS2-treated PCOS (RM), and AX-treated PCOS (AM) groups. The interventions lasted 35 days. Body weight, glucose tolerance, insulin resistance, ovarian morphology, estrous cycles, the gut microbiota (16 S rRNA sequencing), serum SCFA levels, fecal bile acids, and hepatic proteomics (DIA-MS) were analyzed.
resultsRS2 and AX reduced body weight, improved insulin sensitivity (lower HOMA-IR, p < 0.05), restored regular estrous cycles, and mitigated ovarian cystic follicles in PCOS mice. Gut microbiota analysis revealed an increased prevalence of Ligilactobacillus in the RM and AM groups (p < 0.05), which was correlated with elevated SCFA (acetic acid, butyrate) levels. Hepatic proteomics revealed increased expression of AMPK signaling proteins (Prkag2 and Pck1) in treated PCOS mice (p < 0.05), which was linked to the SCFA-mediated activation of GPRs (GPR41/43). AX also modulated pathways associated with nonalcoholic fatty liver disease. Bile acid metabolism showed no significant intervention-related changes.
conclusionRS2 and AX alleviated PCOS phenotypes by enriching Ligilactobacillus, increasing SCFA production, and activating hepatic AMPK signaling. These findings highlight gut microbiota modulation and SCFA-driven metabolic pathways as therapeutic targets for PCOS. This study provides mechanistic insights into dietary fiber interventions for endocrine disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.